Five fusions (XPA-NCBP1, HARS2-ZMAT2, HSP90B1-DKFZp547P055, IL17RB-ACTR8, ANKRD23-ANKRD39) are shared between AML and prostate cancer. Here, NCBP1 is linked to prostate carcinoma.